Movement Disorders (revue) - Checkpoint (Ncbi)

Index « Mesh.i » - entrée « Indans »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Income < Indans < Independent Living  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 28.
[0-20] [0 - 20][0 - 28][20-27][20-40]
Ident.Authors (with country if any)Title
000212 (2000) H H Fernandez [États-Unis] ; J H Friedman ; J. Grace ; S. Beason-HazenDonepezil for Huntington's disease.
000836 (2002) Andrew Siderowf [États-Unis] ; Michael Mcdermott ; Karl Kieburtz ; Karen Blindauer ; Sandra Plumb ; Ira ShoulsonTest-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.
000B15 (2003) Juha-Matti Savola [Finlande] ; Michael Hill ; Mia Engstrom ; Hannele Merivuori ; Siegfried Wurster ; Steven G. Mcguire ; Susan H. Fox ; Alan R. Crossman ; Jonathan M. BrotchieFipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
000E96 (2004) Matthew B. Stern [États-Unis] ; Kenneth L. Marek ; Joseph Friedman ; Robert A. Hauser ; Peter A. Lewitt ; Daniel Tarsy ; C Warren OlanowDouble-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
001217 (2005) Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol ; Cristina SampaioEvidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
001224 (2005) C Warren Olanow [États-Unis] ; Joseph Jankovic [États-Unis]Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
001381 (2005) Anthony E. Lang [Canada]Treatment of progressive supranuclear palsy and corticobasal degeneration.
001496 (2006) Marc J. Mentis [États-Unis] ; Dominique Delalot [États-Unis] ; Hassan Naqvi [États-Unis] ; Mark F. Gordon [États-Unis] ; Mark Gudesblatt [États-Unis] ; Christine Edwards [États-Unis] ; Luke Donatelli [États-Unis] ; Vijay Dhawan [États-Unis] ; David Eidelberg [États-Unis]Anticholinesterase Effect on Motor Kinematic Measures and Brain Activation in Parkinson’s Disease
001556 (2006) Kevin M. Biglan [États-Unis] ; Steven Schwid ; Shirley Eberly ; Karen Blindauer ; Stanley Fahn ; Tamar Goren ; Karl Kieburtz ; David Oakes ; Sandra Plumb ; Andrew Siderowf ; Matthew Stern ; Ira ShoulsonRasagiline improves quality of life in patients with early Parkinson's disease.
001793 (2006) J Antonelle Demarcaida [États-Unis] ; Steven R. Schwid ; William B. White ; Karen Blindauer ; Stanley Fahn ; Karl Kieburtz ; Matthew Stern ; Ira ShoulsonEffects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
001849 (2006) Helmut NiederhoferDonepezil also effective in the treatment of Tourette's syndrome?
001F07 (2008) Sonia Brucki ; Ricardo NitriniCamptocormia in Alzheimer's disease: an association?
001F54 (2008) Francisco Coria [Espagne] ; María Del Puig Cozar-SantiagoRasagiline improves freezing in a patient with primary progressive freezing gait.
002380 (2008) C Warren Olanow [États-Unis] ; Robert A. Hauser ; Joseph Jankovic [États-Unis] ; William Langston ; Anthony Lang ; Werner Poewe [Autriche] ; Eduardo Tolosa ; Fabrizio Stocchi ; Eldad Melamed ; Eli Eyal ; Olivier RascolA randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
002431 (2010) Stuart H. IsaacsonSelective MAO-B inhibitors have low potential for the tyramine effect.
002455 (2009) Robert A. Hauser [États-Unis] ; Mark F. Lew ; Howard I. Hurtig ; William G. Ondo ; Joanne Wojcieszek ; Cheryl J. Fitzer-AttasLong-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
002486 (2009) Nir Giladi [Israël] ; Joseph Tal ; Tali Azulay ; Oliver Rascol ; David J. Brooks ; Eldad Melamed ; Wolfgang Oertel ; Werner Poewe [Autriche] ; Fabrizio Stocchi ; Eduardo TolosaValidation of the freezing of gait questionnaire in patients with Parkinson's disease.
002807 (2009) Rosalind S. Chuang ; Anthony E. LangRasagiline-induced spontaneous ejaculation.
002E52 (2010) Tom H. Johnston [Canada] ; Susan H. Fox ; Matthew J. Piggott ; Juha-Matti Savola ; Jonathan M. BrotchieThe α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.
003015 (2011) Carl Fernandes ; Prashanth Reddy ; Belinda KesselRasagiline-induced serotonin syndrome.
003061 (2011) Robert A. Hauser [États-Unis] ; Peggy AuingerDetermination of minimal clinically important change in early and advanced Parkinson's disease.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i -k "Indans" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i  \
                -Sk "Indans" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Indans
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024